⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Talphera, Inc. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Talphera, Inc.
↗San Mateo, USA
Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. Formerly known as AcelRx Pharmaceuticals, the company rebranded in 2024 to reflect a strategic pivot away from its legacy acute pain focus toward a broader mission of developing specialized medical solutions.
The company's current pipeline is centered on nafamostat-based product candidates, including Niyad, a lyophilized formulation of nafamostat being developed as a regional anticoagulant for use in the extracorporeal circuit (e.g., dialysis). Additionally, the company is developing LTX-608 for various indications such as ARDS and DIC, and has partnered to develop pre-filled syringe products for acute care settings.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Revenue:$0M-$1M
Founded:2005
Ownership:public
Status:operating
FUNDING
Stage:Public
STOCK
Exchange:NASDAQ
Ticker:TLPH
Market Cap:$0.04B
PIPELINE
Stage:Phase 3
Lead Drug Stage:Phase 3 (Niyad)
Modalities:Small molecule
Active Trials:18
Trial Phases:Phase 2: 2 | Phase 3: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Laboratoire Aguettant (pre-filled syringe development)
COMPETITION
Position:Niche Player
Competitors:Heparin manufacturers, Citrate manufacturers
LEADERSHIP
Key Executives:
Vincent J. Angotti - CEO
Pamela P. Palmer - Chief Medical Officer and Co-Founder
Raffi Asadorian - Chief Financial Officer
Scientific Founders:Thomas A. Schreck, Pamela Pierce Palmer
Board Members:Adrian Adams (Chairman)
LINKS
Website:talphera.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Talphera, Inc.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.